Multimodal RNA drugs to reverse resistance and improve clinical outcomes
Multimodal
We combine the potent binding of high performance aptamer binders with the flexible silencing power of RNAi
Multitargeted
SeekRs™ have the unique ability to target 4 or more pathways with a single agent
Multifunctional
SeekRs™ can be directed to any cell type and can be designed to influence a wide spectrum of cellular funtions and clinical phenotypes

SeekRTM Platform
Pipeline of paradigm
shifting RNA therapies
across multiple indications
OligonTM is pioneering a new class of multimodal and multitargeting RNA therapies to transform outcomes for complex diseases
Leadership
Our Executive Leadership Team

Spyro Mousses, PhD
Founder, Chief Executive Officer and Chairman of the Board

Spyro Mousses, PhD
Founder, Chief Executive Officer and Chairman of the Board
Dr. Mousses is widely recognized as a leading scientist in the application of genomics, RNAi, systems biology, and machine learning to improve and accelerate cancer drug discovery and development. He has published more than 60 patents, scientific articles, and book chapters. He served as Director of the Pharmaceutical Genomics Division at the Translational Genomics Research Institute (TGen), where he led 8 laboratories to develop more than 30 programs and collaborated with pharmaceutical partners to accelerate cancer drug development. Prior to that, he served as Staff Scientist at the National Human Genome Research Institute (NHGRI), NIH, leading a program in cancer genome scanning and high throughput technology.
As a successful entrepreneur, Dr. Mousses has previously founded several biotech and IT companies, including Systems Medicine (acquired by Cell Therapeutics), MedTrust Online (acquired by Annai Systems), and Systems Imagination, which offers advanced cognitive computing technology to translate big data into biomedical insights.
Dr. Mousses received his PhD in Molecular Pathogenesis and Genetics of Cancer from the University of Toronto. He can be reached by contacting his EA, Courtney Villani, at
As a successful entrepreneur, Dr. Mousses has previously founded several biotech and IT companies, including Systems Medicine (acquired by Cell Therapeutics), MedTrust Online (acquired by Annai Systems), and Systems Imagination, which offers advanced cognitive computing technology to translate big data into biomedical insights.
Dr. Mousses received his PhD in Molecular Pathogenesis and Genetics of Cancer from the University of Toronto. He can be reached by contacting his EA, Courtney Villani, at
- Email:[email protected]

James Silver, LLM
Chief Operating Officer

James Silver, LLM
Chief Operating Officer
At SO, James advises the CEO and CLO on developing and executing business strategy. This includes structuring and negotiating financings, licenses, acquisitions, partnerships, evaluation of growth opportunities, and other commercial transactions. James is further responsible for operationalizing SO’s corporate development activities, including leading teams in legal, operations, investor relations, public relations, human resources, and facilities. James also serves as the Chair of the Corporate Affairs Committee.
Earlier in his career, James was a biotech attorney in private practice, most recently with Wilson Sonsini Goodrich & Rosati. James was educated at University of Toronto, University of London, and Osgoode Hall Law School, and is admitted to practice law in Massachusetts, New York, and Ontario, and as registered in-house counsel in Arizona.
Earlier in his career, James was a biotech attorney in private practice, most recently with Wilson Sonsini Goodrich & Rosati. James was educated at University of Toronto, University of London, and Osgoode Hall Law School, and is admitted to practice law in Massachusetts, New York, and Ontario, and as registered in-house counsel in Arizona.

Andrew Matricaria, MBA
Chief Financial Officer

Andrew Matricaria, MBA
Chief Financial Officer
Andrew has 20 years of private equity and healthcare industry experience. As Managing Partner of Lakeshore Capital Partners, Andrew is responsible for evaluating potential investment opportunities, structuring and executing transactions and portfolio company oversight. In his role at Lakeshore, Andrew also provides financial consulting and executive-level management services.
Prior to founding Lakeshore Capital Partners, Andrew worked in brand management at Amgen. While at Amgen, he took on increasing levels of responsibility in the sales and marketing organization. In his most recent role, he directed the strategic planning and operations function for a groundbreaking oncology product launch.
Previously, Andrew worked as an investment banking analyst for Credit Suisse First Boston, where he focused on mergers and acquisitions advisory and debt and equity financings.
Andrew holds a BA from the University of Michigan and an MBA from The Fuqua School of Business at Duke University, with a concentration in Health Sector Management.
Prior to founding Lakeshore Capital Partners, Andrew worked in brand management at Amgen. While at Amgen, he took on increasing levels of responsibility in the sales and marketing organization. In his most recent role, he directed the strategic planning and operations function for a groundbreaking oncology product launch.
Previously, Andrew worked as an investment banking analyst for Credit Suisse First Boston, where he focused on mergers and acquisitions advisory and debt and equity financings.
Andrew holds a BA from the University of Michigan and an MBA from The Fuqua School of Business at Duke University, with a concentration in Health Sector Management.
Culture & Careers
A culture of innovation
We aim to change the clinical status quo by pioneering a new approach to treating complex diseases. Disrupting industries takes tremendous grit, commitment, and courage so we believe in a culture that seeks excellence.